The nine month and Q3 2017 results are in for Amyris, and there’s reason for the long-suffering shareholder to take some near-Christmas cheer. YTD revenue is up more than 1/3 and product revenue has more than doubled. Guidance for year-end revenues was upped. The company has found a new deep-pocketed champion in DSM. But there … Continue reading Amyris’ Sweet-‘N-High: Biotech pioneer sells farnesene plant to DSM, focuses on next-gen sweetener